<DOC>
	<DOCNO>NCT00681044</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , certain chemotherapy drug , help stem cell move bone marrow blood collect store . Chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This phase II trial study side effect high-dose melphalan give together stem cell transplant see well work treat patient immunoglobulin deposition disease light-chain deposition disease .</brief_summary>
	<brief_title>HD Melphalan SCT Patients With IGDD LCDD</brief_title>
	<detailed_description>OBJECTIVES : - To assess tolerability high-dose melphalan autologous stem cell transplantation patient immunoglobulin deposition disease light-chain deposition disease . - To determine hematologic response rate patient treat regimen . - To determine predictability early free light-chain response heme response patient treat regimen . - To determine organ clinical response patient treat regimen . - To determine overall survival patient . OUTLINE : - Stem cell mobilization : Patients undergo blood stem cell mobilization comprise filgrastim ( G-CSF ) subcutaneously daily 3 day ( i.e. , day last stem cell collection ) . - Stem cell collection : Patients undergo collection G-CSF-mobilized blood stem cell target number stem cell ( least 2 x 10^6 cluster differentiation-34-positive cell ) reach . - Conditioning regimen : Patients receive high-dose melphalan IV day -3 -2 . - Autologous stem cell transplantation : Patients undergo blood stem cell infusion day 0 . After completion study therapy , patient follow 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lightchain deposition disease base follow criterion : Deposition granular material contain free lightchain ( FLC ) immunoglobulins bind Congo red Evidence plasma cell dyscrasia , define follow : Monoclonal gammopathy serum urine immunofixation electrophoresis Clonal plasmacytosis bone marrow biopsy immunohistochemical Elevated serum level FLC Patients may enroll stem cell collection ( SCC ) prestudy requirement complete prior start SCC ( i.e. , ≥ 2.5 x 10^6 cell available transplantation ) PRIOR CONCURRENT THERAPY : Prior chemotherapy alkylating agent allow provide evidence myelodysplastic syndrome Prior total dose melphalan &lt; 300 mg More 4 week since prior cytotoxic therapy recover PATIENT CHARACTERISTICS : Performance status 02 Left Ventricular Ejection Fraction ( LVEF ) ≥ 45 % within past 90 day diffuse capacity lung carbon monoxide ( DLCO ) ≥ 50 % No overt multiple myeloma , define follow : Greater 30 % bone marrow plasmacytosis Extensive ( i.e. , &gt; 2 ) lytic lesion Hypercalcemia No myocardial infarction , congestive heart failure , arrhythmia refractory therapy within past 6 month No prior malignancy except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer patient currently complete response , cancer patient diseasefree past 5 year No HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>monoclonal immunoglobulin deposition disease</keyword>
	<keyword>light chain deposition disease</keyword>
</DOC>